Article List

WPRIM Management System> DCMS> Asian Journal of Andrology> 2007> 9> 1

Volume: 9 Issue: 1

1. Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign prostatic hyperplasia.	Page:51—56
2. Gene therapy and erectile dysfunction: the current status.	Page:8—15
3. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells.	Page:41—50
4. Improvement in erectile dysfunction after insulin-like growth factor-1 gene therapy in diabetic rats.	Page:83—91
5. Influence of enterococci on human sperm membrane in vitro.	Page:77—81
6. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial.	Page:134—141
7. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders.	Page:129—133
8. Protective effects of vitamin E on ethane dimethane sulfonate-induced testicular toxicity in rats.	Page:117—124
9. Increased oxidative damage of sperm and seminal plasma in men with idiopathic infertility is higher in patients with glutathione S-transferase Mu-1 null genotype.	Page:108—115
10. Sperm lipid peroxidation and pro-inflammatory cytokines.	Page:102—107
11. Seasonal variation in semen quality of swamp buffalo bulls (Bubalus bubalis) in Thailand.	Page:92—101
12. Frequency of Y chromosome microdeletions and chromosomal abnormalities in infertile Thai men with oligozoospermia and azoospermia.	Page:68—75
13. Assessment of seminal plasma laminin in fertile and infertile men.	Page:63—67
14. Alpha-vitamin E derivative, RRR-alpha-tocopheryloxybutyric acid inhibits the proliferation of prostate cancer cells.	Page:31—39
15. Inhibition of mouse acrosome reaction and sperm-zona pellucida binding by anti-human sperm membrane protein 1 antibody.	Page:23—29
16. Hypospadias: an update.	Page:16—22
17. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.	Page:3—7